论文部分内容阅读
目的为探讨拉米夫啶联合软肝缩脾丸治疗对慢性乙型肝炎患者血清肝纤维化指标、B超声像图及肝脏病理组织学的影响。方法随机选择32例慢性乙型肝炎患者作为治疗组,给予口服拉米夫啶0.1g/d,并同时口服软肝缩脾丸8g/次,2次/d,疗程48周;同时设对照组,单服拉米夫啶100mg,1次/d。动态观察服药0、48周患者血清中肝纤维化指标的变化,B型超声图像变化,对其中4例患者治疗前后肝穿活检观察肝组织纤维化程度的改变。结果与对照组相比,治疗组患者血清肝纤维化指标明显下降(P<0.01),B超声像图改变(P<0.05),肝组织纤维化明显减轻。结论拉米夫啶联合软肝缩脾丸治疗慢性乙型肝炎,在抗肝纤维化、减轻肝细胞损伤方面有较佳疗效。
Objective To explore the effect of lamivudine combined with Ruangan Sippo Pill on serum hepatic fibrosis index, B ultrasound image and liver histology in patients with chronic hepatitis B. Methods Thirty-two patients with chronic hepatitis B were randomly selected as the treatment group. Oral Lamivudine 0.1 g / d was given orally and Ruangongxiao Pill 8g / time, 2 times / d orally for 48 weeks. At the same time, , Single service Lamivudine 100mg, 1 time / d. Changes of liver fibrosis index and B-mode ultrasound in patients with medication at 0 and 48 weeks were observed dynamically. Changes of liver fibrosis were observed in 4 patients before and after liver biopsy. Results Compared with the control group, the serum hepatic fibrosis index of the treatment group was significantly decreased (P <0.01), B ultrasound image was changed (P <0.05), liver fibrosis was significantly reduced. Conclusions Lamivudine combined with Ruannansuoxue Pills in the treatment of chronic hepatitis B is effective in preventing liver fibrosis and reducing the damage of liver cells.